Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression

Psychoneuroendocrinology

Volumn 38, Issue 6, 2013, Pages 767-776

  Kashani, Ladan ^a   Omidvar, Targol ^b   Farazmand, Behnoud ^b   Modabbernia, Amirhossein ^b   Ramzanzadeh, Fatemeh ^c   Tehraninejad, Ensiyeh Shahrokh ^c   Ashrafi, Mandana ^b   Tabrizi, Mina ^c   Akhondzadeh, Shahin ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Insulin resistance; Major depressive disorder; Metformin; Pioglitazone; Polycystic ovarian syndrome; PPAR gamma; Thiazolidinediones

Indexed keywords

ANDROGEN; GLUCOSE; INSULIN; LIPID; LIVER ENZYME; METFORMIN; PIOGLITAZONE;

ABDOMINAL PAIN; ADULT; ANDROGEN BLOOD LEVEL; ANTHROPOMETRY; APPETITE; ARTICLE; BLOATING; BLURRED VISION; COMORBIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; ENZYME BLOOD LEVEL; FEMALE; GASTROINTESTINAL SYMPTOM; HAMILTON SCALE; HEADACHE; HOMEOSTATIC MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MYALGIA; NAUSEA; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SORE THROAT; VOMITING;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; BIOLOGICAL MARKERS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METFORMIN; OBESITY; POLYCYSTIC OVARY SYNDROME; THIAZOLIDINEDIONES;

EID: 84877080516     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2012.08.010     Document Type: Article

References (68)

1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril. 2004, 81:19-25.
2. Abbasi S.H., Hosseini F., Modabbernia A., Ashrafi M., Akhondzadeh S. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J. Affect. Disord. 2012, 10.1016/j.jad.2012.03.033.
3. Adam C.L., Findlay P.A., Aitken R.P., Milne J.S., Wallace J.M. In vivo changes in central and peripheral insulin sensitivity in a large animal model of obesity. Endocrinology 2012, 153:3147-3157.
4. Adriaanse M.C., Dekker J.M., Nijpels G., Heine R.J., Snoek F.J., Pouwer F. Associations between depressive symptoms and insulin resistance: the Hoorn study. Diabetologia 2006, 49:2874-2877.
5. Akhondzadeh S., Jafari S., Raisi F., Nasehi A.A., Ghoreishi A., Salehi B., Mohebbi-Rasa S., Raznahan M., Kamalipour A. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress. Anxiety 2009, 26:607-611.
6. Almeida O.P., Calver J., Jamrozik K., Hankey G.J., Flicker L. Obesity and metabolic syndrome increase the risk of incident depression in older men: the health in men study. Am. J. Geriatr. Psychiatry 2009, 17:889-898.
7. Aroda V.R., Ciaraldi T.P., Burke P., Mudaliar S., Clopton P., Phillips S., Chang R.J., Henry R.R. Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. J. Clin. Endocrinol. Metab. 2009, 94:469-476.
8. Asadabadi M., Mohammadi M.R., Ghanizadeh A., Modabbernia A., Ashrafi M., Hassanzadeh E., Forghani S., Akhondzadeh S. Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Psychopharmacology (Berl.) 2012, 10.1007/s00213-012-2796-8.
9. Barry J.A., Kuczmierczyk A.R., Hardiman P.J. Anxiety and depression in polycystic ovary syndrome: a systematic review and meta-analysis. Hum. Reprod. 2011, 26:2442-2451.
10. Boris M., Kaiser C.C., Goldblatt A., Elice M.W., Edelson S.M., Adams J.B., Feinstein D.L. Effect of pioglitazone treatment on behavioral symptoms in autistic children. J. Neuroinflam. 2007, 4:3.
11. Budni J., Lobato K.R., Binfare R.W., Freitas A.E., Costa A.P., Saavedra M.D., Leal R.B., Lopez M.G., Rodrigues A.L. Involvement of PI3K GSK-3beta and PPARgamma in the antidepressant-like effect of folic acid in the forced swimming test in mice. J. Psychopharmacol. 2012, 26:714-723.
12. Chen H., Sullivan G., Yue L.Q., Katz A., Quon M.J. QUICKI is a useful index of insulin sensitivity in subjects with hypertension. Am. J. Physiol. Endocrinol. Metab. 2003, 284:E804-E812.
13. Chen Y.C., Lin W.W., Chen Y.J., Mao W.C., Hung Y.J. Antidepressant effects on insulin sensitivity and proinflammatory cytokines in the depressed males. Mediat. Inflamm. 2010, 2010:573-594.
14. d'Abramo C., Ricciarelli R., Pronzato M.A., Davies P. Troglitazone, a peroxisome proliferator-activated receptor-gamma agonist, decreases tau phosphorylation in CHOtau4R cells. J. Neurochem. 2006, 98:1068-1077.
15. Dale P.O., Tanbo T., Vaaler S., Abyholm T. Body weight, hyperinsulinemia, and gonadotropin levels in the polycystic ovarian syndrome: evidence of two distinct populations. Fertil. Steril. 1992, 58:487-491.
16. De La Monte S.M. Metabolic derangements mediate cognitive impairment and Alzheimer's disease: role of peripheral insulin-resistance diseases. Panmin. Med. 2012, 54:171-178.
17. Du Q., Wang Y.J., Yang S., Wu B., Han P., Zhao Y.Y. A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. Curr. Med. Res. Opin. 2012, 28:723-730.
18. Eissa Ahmed A.A., Al-Rasheed N.M. Antidepressant-like effects of rosiglitazone, a PPARgamma agonist, in the rat forced swim and mouse tail suspension tests. Behav. Pharmacol. 2009, 20:635-642.
19. Everson-Rose S.A., Meyer P.M., Powell L.H., Pandey D., Torrens J.I., Kravitz H.M., Bromberger J.T., Matthews K.A. Depressive symptoms, insulin resistance, and risk of diabetes in women at midlife. Diabetes Care 2004, 27:2856-2862.
20. Fuenzalida K., Quintanilla R., Ramos P., Piderit D., Fuentealba R.A., Martinez G., Inestrosa N.C., Bronfman M. Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J. Biol. Chem. 2007, 282:37006-37015.
21. Garcia-Bueno B., Perez-Nievas B.G., Leza J.C. Is there a role for the nuclear receptor PPARgamma in neuropsychiatric diseases?. Int. J. Neuropsychopharmacol. 2010, 13:1411-1429.
22. Gupta A., Bisht B., Dey C.S. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Neuropharmacology 2011, 60:910-920.
23. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960, 23:56-62.
24. Heneka M.T., Landreth G.E. PPARs in the brain. Biochim. Biophys. Acta 2007, 1771:1031-1045.
25. Jedel E., Gustafson D., Waern M., Sverrisdottir Y.B., Landen M., Janson P.O., Labrie F., Ohlsson C., Stener-Victorin E. Sex steroids, insulin sensitivity and sympathetic nerve activity in relation to affective symptoms in women with polycystic ovary syndrome. Psychoneuroendocrinology 2011, 36:1470-1479.
26. Jedel E., Waern M., Gustafson D., Landen M., Eriksson E., Holm G., Nilsson L., Lind A.K., Janson P.O., Stener-Victorin E. Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index. Hum. Reprod. 2010, 25:450-456.
27. Ji H., Wang H., Zhang F., Li X., Xiang L., Aiguo S. PPARgamma agonist pioglitazone inhibits microglia inflammation by blocking p38 mitogen-activated protein kinase signaling pathways. Inflamm. Res. 2010, 59:921-929.
28. Jope R.S. Glycogen synthase kinase-3 in the etiology and treatment of mood disorders. Front. Mol. Neurosci. 2011, 4:16.
29. Kaiser C.C., Shukla D.K., Stebbins G.T., Skias D.D., Jeffery D.R., Stefoski D., Katsamakis G., Feinstein D.L. A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis. J. Neuroimmunol. 2009, 211:124-130.
30. Kalonia H., Kumar P., Kumar A. Pioglitazone ameliorates behavioral, biochemical and cellular alterations in quinolinic acid induced neurotoxicity: possible role of peroxisome proliferator activated receptor-Upsilon (PPARUpsilon) in Huntington's disease. Pharmacol. Biochem. Behav. 2010, 96:115-124.
31. Karege F., Perroud N., Burkhardt S., Fernandez R., Ballmann E., La Harpe R., Malafosse A. Protein levels of beta-catenin and activation state of glycogen synthase kinase-3beta in major depression. A study with postmortem prefrontal cortex. J. Affect. Disord. 2012, 136:185-188.
32. Kemp D.E., Ismail-Beigi F., Calabrese J.R. Antidepressant response associated with pioglitazone: support for an overlapping pathophysiology between major depression and metabolic syndrome. Am. J. Psychiatry 2009, 166:619.
33. Kemp D.E., Ismail-Beigi F., Ganocy S.J., Conroy C., Gao K., Obral S., Fein E., Findling R.L., Calabrese J.R. Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity. J. Affect. Disord. 2012, 136:1164-1173.
34. Kim C.H., Ahn J.W., You R.M., Kim S.H., Chae H.D., Kang B.M. Pioglitazone treatment decreases follicular fluid levels of tumor necrosis factor-alpha and interleukin-6 in patients with polycystic ovary syndrome. Clin. Exp. Reprod. Med. 2011, 38:98-102.
35. Kim C.H., Jeon G.H., Kim S.R., Kim S.H., Chae H.D., Kang B.M. Effects of pioglitazone on ovarian stromal blood flow, ovarian stimulation, and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertil. Steril. 2010, 94:236-241.
36. Kim E.J., Kwon K.J., Park J.Y., Lee S.H., Moon C.H., Baik E.J. Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2. Brain Res. 2002, 941:1-10.
37. Koponen H., Jokelainen J., Keinanen-Kiukaanniemi S., Kumpusalo E., Vanhala M. Metabolic syndrome predisposes to depressive symptoms: a population-based 7-year follow-up study. J. Clin. Psychiatry 2008, 69:178-182.
38. Legro R.S., Zaino R.J., Demers L.M., Kunselman A.R., Gnatuk C.L., Williams N.I., Dodson W.C. The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. Am. J. Obstet. Gynecol. 2007, 196. pp. 402.e1-402.e10 (discussion 402.e10-1).
39. Lewis J.D., Ferrara A., Peng T., Hedderson M., Bilker W.B., Quesenberry C.P., Vaughn D.J., Nessel L., Selby J., Strom B.L. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011, 34:916-922.
40. Li W., Macdonald T.M., Mackenzie I.S. Pioglitazone and bladder cancer: a propensity score matched cohort study. Br. J. Clin. Pharmacol. 2012, 10.1111/j.1365-2125.2012.04325.x.
41. Louise S., Warrington N.M., McCaskie P.A., Oddy W.H., Zubrick S.R., Hands B., Mori T.A., Briollais L., Silburn S., Palmer L.J., Mattes E., Beilin L.J. Associations between anxious-depressed symptoms and cardiovascular risk factors in a longitudinal childhood study. Prev. Med. 2012, 54:345-350.
42. Miller B.W., Willett K.C., Desilets A.R. Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease. Ann. Pharmacother. 2011, 45:1416-1424.
43. Monte S.V., Schentag J.J., Adelman M.H., Paladino J.A. Glucose supply and insulin demand dynamics of antidiabetic agents. J. Diabetes Sci. Technol. 2010, 4:365-381.
44. Muller N., Schwarz M.J., Dehning S., Douhe A., Cerovecki A., Goldstein-Muller B., Spellmann I., Hetzel G., Maino K., Kleindienst N., Moller H.J., Arolt V., Riedel M. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol. Psychiatry 2006, 11:680-684.
45. Munhoz C.D., Garcia-Bueno B., Madrigal J.L., Lepsch L.B., Scavone C., Leza J.C. Stress-induced neuroinflammation: mechanisms and new pharmacological targets. Braz. J. Med. Biol. Res. 2008, 41:1037-1046.
46. Muschamp J.W., Van't Veer A., Carlezon W.A. Tracking down the molecular substrates of stress: new roles for p38alpha MAPK and kappa-opioid receptors. Neuron 2011, 71:383-385.
47. Neumann A., Weill A., Ricordeau P., Fagot J.P., Alla F., Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 2012, 55:1953-1962.
48. Okamura F., Tashiro A., Utumi A., Imai T., Suchi T., Tamura D., Sato Y., Suzuki S., Hongo M. Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metabolism. 2000, 49:1255-1260.
49. Phielix E., Szendroedi J., Roden M. The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact. Trends Pharmacol. Sci. 2011, 32:607-616.
50. Pipatpiboon N., Pratchayasakul W., Chattipakorn N., Chattipakorn S.C. PPARgamma agonist improves neuronal insulin receptor function in hippocampus and brain mitochondria function in rats with insulin resistance induced by long term high-fat diets. Endocrinology 2012, 153:329-338.
51. Ponce-Lopez T., Liy-Salmeron G., Hong E., Meneses A. Lithium, phenserine, memantine and pioglitazone reverse memory deficit and restore phospho-GSK3beta decreased in hippocampus in intracerebroventricular streptozotocin induced memory deficit model. Brain Res. 2011, 1426:73-85.
52. Pontes A.G., Rehme M.F., Martins A.M., Micussi M.T., Maranhao T.M., Pimenta Wde P., Pontes A. Insulin resistance in women with polycystic ovary syndrome: relationship with anthropometric and biochemical variables. Rev. Bras. Ginecol. Obstet. 2012, 34:74-79.
53. Rasgon N.L., Carter M.S., Elman S., Bauer M., Love M., Korenman S.G. Common treatment of polycystic ovarian syndrome and major depressive disorder: case report and review. Curr. Drug Targets Immune Endocr. Metabol. Disord. 2002, 2:97-102.
54. Rasgon N.L., Kenna H.A., Williams K.E., Powers B., Wroolie T., Schatzberg A.F. Rosiglitazone add-on in treatment of depressed patients with insulin resistance: a pilot study. ScientificWorldJournal 2010, 10:321-328.
55. Rosa A.O., Kaster M.P., Binfare R.W., Morales S., Martin-Aparicio E., Navarro-Rico M.L., Martinez A., Medina M., Garcia A.G., Lopez M.G., Rodrigues A.L. Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1549-1556.
56. Ryan J.P., Sheu L.K., Critchley H.D., Gianaros P.J. A neural circuitry linking insulin resistance to depressed mood. Psychosom. Med. 2012, 74:476-482.
57. Sadaghiani M.S., Javadi-Paydar M., Gharedaghi M.H., Fard Y.Y., Dehpour A.R. Antidepressant-like effect of pioglitazone in the forced swimming test in mice: the role of PPAR-gamma receptor and nitric oxide pathway. Behav. Brain Res. 2011, 224:336-343.
58. Salehi-Sadaghiani M., Javadi-Paydar M., Gharedaghi M.H., Zandieh A., Heydarpour P., Yousefzadeh-Fard Y., Dehpour A.R. NMDA receptor involvement in antidepressant-like effect of pioglitazone in the forced swimming test in mice. Psychopharmacology (Berl.) 2012, 10.1007/s00213-012-2722-0.
59. Sepanjnia K., Modabbernia A., Ashrafi M., Modabbernia M.J., Akhondzadeh S. Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial. Neuropsychopharmacology 2012, 37:2093-2100.
60. Shomaker L.B., Tanofsky-Kraff M., Young-Hyman D., Han J.C., Yanoff L.B., Brady S.M., Yanovski S.Z., Yanovski J.A. Psychological symptoms and insulin sensitivity in adolescents. Pediatr. Diabetes 2010, 11:417-423.
61. Skrha J., Haas T., Sindelka G., Prazny M., Widimsky J., Cibula D., Svacina S. Comparison of the insulin action parameters from hyperinsulinemic clamps with homeostasis model assessment and QUICKI indexes in subjects with different endocrine disorders. J. Clin. Endocrinol. Metab. 2004, 89:135-141.
62. Spiegelman B.M. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998, 47:507-514.
63. Timonen M., Laakso M., Jokelainen J., Rajala U., Meyer-Rochow V.B., Keinanen-Kiukaanniemi S. Insulin resistance and depression: cross-sectional study. BMJ 2005, 330:17-18.
64. Timonen M., Salmenkaita I., Jokelainen J., Laakso M., Harkonen P., Koskela P., Meyer-Rochow V.B., Peitso A., Keinanen-Kiukaanniemi S. Insulin resistance and depressive symptoms in young adult males: findings from Finnish military conscripts. Psychosom. Med. 2007, 69:723-728.
65. Trivedi M.H., Greer T.L., Church T.S., Carmody T.J., Grannemann B.D., Galper D.I., Dunn A.L., Earnest C.P., Sunderajan P., Henley S.S., Blair S.N. Exercise as an augmentation treatment for nonremitted major depressive disorder: a randomized, parallel dose comparison. J. Clin. Psychiatry 2011, 72:677-684.
66. Wongwananuruk T., Rattanachaiyanont M., Leerasiri P., Indhavivadhana S., Techatraisak K., Angsuwathana S., Tanmahasamut P., Dangrat C. The usefulness of homeostatic measurement assessment-insulin resistance (HOMA-IR) for detection of glucose intolerance in Thai women of reproductive age with polycystic ovary syndrome. Int. J. Endocrinol. 2012, 2012:571035.
67. Yilmaz M., Karakoc A., Toruner F.B., Cakir N., Tiras B., Ayvaz G., Arslan M. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Gynecol. Endocrinol. 2005, 21:154-160.
68. Zeman M., Jirak R., Jachymova M., Vecka M., Tvrzicka E., Zak A. Leptin, adiponectin, leptin to adiponectin ratio and insulin resistance in depressive women. Neuro Endocrinol. Lett. 2009, 30:387-395.